Abstract
The transcription factor E2F-1 induces cell cycle progression at the G1/S checkpoint, and deregulation of E2F-1 provokes apoptosis in a wide variety of malignant cells. To date only p14ARF and p73, a p53 homologue, have been identified as E2F-1-inducible genes capable of mediating an apoptotic response. Here we show that adenovirus-mediated E2F-1 overexpression in cancer cells induces expression and autophosphorylation of the double-stranded RNA-dependent protein kinase PKR leading to phosphorylation of its downstream target, the α-subunit of the eukaryotic translation initiation factor 2 (eIF-2α) and to apoptotic cell death. This PKR-dependent apoptosis occurs in cell lines with mutated p53 and in cell lines with mutated p53 and p73, and is significantly reduced by the chemical inhibition of PKR activation. Further, PKR−/− mouse embryo fibroblasts, but not PKR+/+ mouse embryo fibroblasts, demonstrate significant resistance to E2F-1-induced apoptosis. We conclude that an important pathway of E2F-1-mediated apoptosis is dependent on PKR activation and does not require p53 or p73.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams PD, Kaelin Jr WG . 1996 Curr. Top. Microbiol. Immunol. 208: 79–93
Aktas H, Fluckiger R, Acosta JA, Savage JM, Palakurthi SS, Halperin JA . 1998 Proc. Natl. Acad. Sci. USA 95: 8280–8285
Andrews NC . 1991 Nucleic Acids Res. 19: 2499
Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN . 1998 EMBO J. 17: 6888–6902
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH . 1998 Nature 395: 124–125
Blair LA, Heitmeier MR, Scarim AL, Maggi Jr LB, Corbett JA . 2001 Diabetes 50: 283–290
Carpick BW, Graziano V, Schneider D, Maitra RK, Lee X, Williams BR . 1997 J. Biol. Chem. 272: 9510–9516
Chong KL, Feng L, Schappert K, Meurs E, Donahue TF, Friesen JD, Hovanessian AG, Williams BR . 1992 EMBO J. 11: 1553–1562
Cuddihy AR, Wong AH, Tam NW, Li S, Koromilas AE . 1999 Oncogene 18: 2690–2702
DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR . 1997 Proc. Natl. Acad. Sci. USA 94: 7245–7250
Dever TE, Chen JJ, Barber GN, Cigan AM, Feng L, Donahue TF, London IM, Katze MG, Hinnebusch AG . 1993 Proc. Natl. Acad. Sci. USA 90: 4616–4620
Dynlacht BD, Brook A, Dembski M, Yenush L, Dyson N . 1994 Proc. Natl. Acad. Sci. USA 91: 6359–6363
Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM, Orkin SH, Greenberg ME . 1996 Cell 85: 549–561
Galabru J, Katze MG, Robert N, Hovanessian AG . 1989 Eur. J. Biochem. 178: 581–589
Gil J, Rullas J, Garcia MA, Alcami J, Esteban M . 2001 Oncogene 20: 385–394
Gusella GL, Musso T, Rottschafer SE, Pulkki K, Varesio L . 1995 J. Immunol. 154: 345–354
Haines III GK, Becker S, Ghadge G, Kies M, Pelzer H, Radosevich JA . 1993 Arch. Otolaryngol. Head Neck Surg. 119: 1142–1147
Hovanessian AG, Galabru J . 1987 Eur. J. Biochem. 167: 467–473
Hsieh JK, Fredersdord S, Kouzarides T, Martin K, Lu X . 1997 Genes Dev. 11: 1840–1852
Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G, Hung MC . 1997 CancerRes. 57: 4722–4726
Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin Jr WG . 2000 Nature 407: 645–648
Ishii T, Kwon H, Hiscott J, Mosialos G, Koromilas AE . 2001 Oncogene 20: 1900–1912
Ito T, Yang M, May WS . 1999 J. Biol. Chem. 274: 15427–15432
Jagus R, Joshi B, Barber GN . 1999 Int. J. Biochem. Cell Biol. 31: 123–138
Katze MG . 1992 J. Interferon Res. 12: 241–248
Klefstrom J, Arighi E, Littlewood T, Jaattela M, Saksela E, Evan GI, Alitalo K . 1997 EMBO J. 16: 7382–7392
Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR . 1998 Cell Growth Differ. 9: 113–118
Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin Jr WG, Livingston DM . 1994 Cell 78: 161–172
Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR . 1994 Proc. Natl. Acad. Sci. USA 91: 6288–6292
Kumar A, Yang YL, Flati V, Der S, Kadereit S, Deb A, Haque J, Reis L, Weissmann C, Williams BR . 1997 EMBO J. 16: 406–416
Lieber A, He CY, Kirillova I, Kay MA . 1996 J. Virol. 70: 8944–8960
Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K . 2001 Genes Dev. 15: 267–285
Mundschau LJ, Faller DV . 1995 J. Biol. Chem. 270: 3100–3106
Pain VM . 1996 Eur. J. Biochem. 236: 747–771
Patel CV, Handy I, Goldsmith T, Patel RC . 2000 J. Biol. Chem. 275: 37993–37998
Patel RC, Sen GC . 1998 Mol. Cell Biol. 18: 7009–7019
Patel RC, Vestal DJ, Xu Z, Bandyopadhyay S, Guo W, Erme SM, Williams BR, Sen GC . 1999 J. Biol. Chem. 274: 20432–20437
Pellegrini S, Schindler C . 1993 Trends Biochem. Sci. 18: 338–342
Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH . 1997 Genes Dev. 11: 1853–1863
Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH . 1999 Mol. Cell 4: 771–781
Prostko CR, Dholakia JN, Brostrom MA, Brostrom CO . 1995 J. Biol. Chem. 270: 6211–6215
Rebollo A, Dumoutier L, Renauld JC, Zaballos A, Ayllon V, Martinez A . 2000 Mol. Cell Biol. 20: 3407–3416
Rice AP, Duncan R, Hershey JW, Kerr IM . 1985 J. Virol. 54: 894–898
Samuel CE . 1992 Pharmacol. Ther. 54: 307–317
Samuel CE . 1993 J. Biol. Chem. 268: 7603–7606
Savinova O, Joshi B, Jagus R . 1999 Int. J. Biochem. Cell Biol. 31: 175–189
Shan B, Farmer AA, Lee WH . 1996 Cell Growth Differ. 7: 689–697
Tanaka H, Samuel CE . 1994 Proc. Natl. Acad. Sci. USA 91: 7995–7999
Tanaka H, Samuel CE . 2000 Gene 246: 373–382
Wang D, Russell JL, Johnson DG . 2000 Mol. Cell Biol. 20: 3417–3424
Wathelet MG, Clauss IM, Paillard FC, Huez GA . 1989 Eur. J. Biochem. 184: 503–509
Wong AH, Durbin JE, Li S, Dever TE, Decker T, Koromilas AE . 2001 J. Biol. Chem. 276: 13727–13737
Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A, Williams BR, Aguet M, Weissmann C . 1995 EMBO J. 14: 6095–6106
Yeung MC, Lau AS . 1998 J. Biol. Chem. 273: 25198–25202
Yeung MC, Liu J, Lau AS . 1996 Proc. Natl. Acad. Sci. USA 93: 12451–12455
Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K, Harris CC . 1999 Oncogene 18: 3415–3421
Zamanian-Daryoush M, Der SD, Williams BR . 1999 Oncogene 18: 315–326
Zinn K, Keller A, Whittemore LA, Maniatis T . 1988 Science 240: 210–213
Acknowledgements
The authors are grateful to Dr Jian Gu (University of Texas M.D. Anderson Cancer Center) for his help with real-time PCR; Stephanie Deming for her editorial assistance and Mary Elliott for preparation of the manuscript. This investigation was supported in part by the University of Texas M.D. Anderson Cancer Center Support Core Grant (CA 16672), from the National Institute of Health, Department of Health & Human Services, the Department of Defense DAMD17-97-1-7162 (KK Hunt), and the Swiss Cancer League grant BIL SKL 1129-02-2001; and the Foundation for Cancer Treatment grant 148 (SA Vorburger).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vorburger, S., Pataer, A., Yoshida, K. et al. Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis. Oncogene 21, 6278–6288 (2002). https://doi.org/10.1038/sj.onc.1205761
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205761
Keywords
This article is cited by
-
Dual induction of PKR with E2F-1 and IFN-α to enhance gene therapy against hepatocellular carcinoma
Cancer Gene Therapy (2008)
-
E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation
BMC Cancer (2007)
-
Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl- amino-17-demethoxy analogue
Cancer Gene Therapy (2007)
-
E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway
Oncogene (2006)
-
Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation
Oncogene (2005)